ClinicalTrials.gg
CompletedNCT00797966Updated Feb 29, 2016Results posted

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

A Phase 2 interventional study of OPC-34712 and Placebo in Major Depressive Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 50 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-02-29.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
850
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.

Enrollment
6th of 24
850 · median 189
Started
2009
with 1 other
Phase 2
3 of 24
none open now
Registered
1st of 24
by date
Lead sponsor
15 of 24
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 6th largest by enrollment, is one of 2 that started in 2009, is one of 3 in phase 2, and was the 1st registered.

Depressive Disorder, Major

3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 297 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing brexpiprazole in Depressive Disorder, Major, or all of them as a file.
02

Study summary

Primary: To compare the efficacy of OPC-34712 to placebo as adjunctive treatment to an assigned open-label marketed antidepressant treatment (ADT)in patients who demonstrate an incomplete response to a prospective eight week trial of the same assigned open-label marketed ADT.

Read the detailed description

A comparison of the Fixed dose arm (OPC-31712, 0.15 mg) verses placebo was included as a general secondary efficacy variable and results for this dose group comparison are included under each of the Outcome Measures.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • OPC-34712, Major Depressive Disorder, Adjunctive Treatment
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between 18 and 65 years of age, with diagnosis of major depressive disorder, as defined by criteria
  • The current depressive episode must be equal to or greater than 8 weeks in duration
  • Subjects must report a history for the current depressive episode of an inadequate response to at least one and no more than three adequate antidepressant treatments.

Exclusion criteria

Exclusion Criteria:

  • Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug.
  • Subjects who report an inadequate response to more than three adequate trials of antidepressant treatments during current depressive episode at a therapeutic dose for an adequate duration.
  • Subjects with a current Axis I () diagnosis of:

    • Delirium, dementia,amnestic or other cognitive disorder
    • Schizophrenia, schizoaffective disorder, or other psychotic disorder
    • Bipolar I or II disorder
    • Subjects with a current Axis II (DSM-IV-TR)
    • diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
850 participants (actual)

Study arms

  • Experimental
    1

    OPC-34712 + ADT

    Drug: OPC-34712 · Drug: ADT

  • Placebo comparator
    2

    Placebo + ADT

    Drug: Placebo · Drug: ADT

Interventions

  • DrugBrexpiprazoleStudies of BrexpiprazoleBrexpiprazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Tablets, Oral, 1 - 4 mg OPC-34712 variable dose once daily, 14 weeks

    Also known as: Generic Name: Brexpiprazole

  • DrugPlacebo

    Tablets, Oral, 1- 4 mg OPC-34712 once daily, 14 weeks

  • DrugAntiandrogensStudies of AntiandrogensAntiandrogens pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Tablets, 10 - 225 mgs, dose once daily, 14 weeks

    Also known as: Each individual will receive one of the following 6 ADTs:, Escitalopram (Lexapro), Fluoxetine (Prozac), Paroxetine CR (Paxil CR), Sertraline (Zoloft), Desvenlafaxine (Pristiq), Venalfaxine XR (Effexor XR)

06

What researchers measure

Primary outcomes

  1. Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score.

    The MADRS is utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items. The possible Total scores are from 0 to 60. The MADRS Total Score was unevaluable if less than 8 of the 10 items are recorded. If 8 or 9 of the 10 items were recorded, the MADRS Total Score was the mean of the recorded items multiplied by 10 and then rounded to the first decimal place.

    Time frame: Week 8 to Week 14

Secondary outcomes

  1. Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Clinical Global Impression - Severity of Illness Scale (CGI-S) Score.

    CGI-S items are: 0 = not assessed, 1 = normal, not at all ill, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill patients. The score 0 (= not assessed) was set to missing. The CGI-S was therefore a 7-point scale from 1 through 7. CGI-S was assessed at screening, baseline and each subsequent visit from Week 1 through Week 14.

    Time frame: Week 8 to Week 14

  2. Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Quality of Life, Enjoyment, and Satisfaction Questionnaire - Short Form (QLES-Q-SF) Subscale Score - the Overall General Subscore (Sum of First 14 Items).

    The Q-LES-Q is a self-report measure to enable physicians to obtain sensitive measures of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning. Each item is scored on a five-point scale, with 1= Very Poor; 2=Poor; 3=Fair; 4=Good; 5=Very Good. Lower scores indicating less enjoyment or satisfaction with the activity. The Overall-General Subscore will be defined by summing the scores on all 14 items and expressing it as the percent of the maximum possible score. When expressing the total score as a percentage, if items are left blank the range will be modified to reflect the number of items scored. Raw score is sum of non-missing ratings from items 1 to 14. Minimum score is number of non-missing items. Maximum score is 5\*(minimum score). Range is maximum score minus minimum score. Total score is 100\*(Raw score minus minimum score)/ Range, rounded to nearest integer.

    Time frame: Week 8 to Week 14

  3. Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Sheehan Disability Scale (SDS) Mean Score (the Mean of 3 Individual Item Scores).

    The Sheehan Disability Scale (SDS) is a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS Score will be calculated over the three item scores. All three item scores need to be available with the exception of the work/school item score when this item is not applicable.

    Time frame: Week 8 to Week 14

  4. Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Study Week Visit in Phase B Other Than the Week 14 Visit.

    The MADRS is utilized as the primary efficacy assessment of a patient's level of depression. The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items. The possible Total scores are from 0 to 60. The MADRS Total Score was unevaluable if less than 8 of the 10 items are recorded. If 8 or 9 of the 10 items were recorded, the MADRS Total Score was the mean of the recorded items multiplied by 10 and then rounded to the first decimal place.

    Time frame: Week 8 to each of Week 9, 10, 11, 12 and 13.

  5. Change From End of Phase A (Week 8 Visit) in Mean CGI-S Score for Every Study Week Visit in Phase B Other Than the Week 14 Visit.

    CGI-S items are: 0 = not assessed, 1 = normal, not at all ill, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill patients. The score 0 (= not assessed) was set to missing. The CGI-S was therefore a 7-point scale from 1 through 7. CGI-S was assessed at screening, baseline and each subsequent visit from Week 1 through Week 14.

    Time frame: Week 8 to each of Week 9, 10, 11, 12 and 13.

  6. Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 15 Score (Satisfaction With Medication).

    The Q-LES-Q (Short Form) is a self-report measure designed to enable physicians to easily obtain sensitive measures of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning. Each item is scored on a five-point scale, with 1= Very Poor; 2=Poor; 3=Fair; 4=Good; 5=Very Good. Lower scores indicating less enjoyment or satisfaction with the activity. According to the scoring system suggested for this questionnaire, item 15 (Satisfaction with Medication) will yield a separate subscore.

    Time frame: Week 8 to Week 14

  7. Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 16 Score (Overall Life Satisfaction).

    The Q-LES-Q (Short Form) is a self-report measure designed to enable physicians to easily obtain sensitive measures of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning. Each item is scored on a five-point scale, with 1= Very Poor; 2=Poor; 3=Fair; 4=Good; 5=Very Good. Lower scores indicating less enjoyment or satisfaction with the activity. According to the scoring system suggested for this questionnaire, item 16 (Overall Life Satisfaction) will yield a separate subscore.

    Time frame: Week 8 to Week 14

  8. Change From End of Phase A (Week 8 Visit) for Every Study Week Visit in Phase B in Inventory of Depressive Symptomatology (Self-Report) (IDS-SR) Total Score.

    The IDS-SR is a 30-item self-report measure used to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of major depressive disorders. The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. The IDS-SR Total Score is the sum of ratings of 28 item scores. The possible IDS-SR Total Score ranges from 0 to 84. The IDS-SR Total Score was un-evaluable if less than 23 of the 28 items are recorded. If the number of items was at least 23 and at most 27, the IDS-SR Total Score will be the mean of the recorded items multiplied by 28 and then rounded to the first decimal place.

    Time frame: Week 8 to each of Week 9, 10, 11, 12, 13 and 14

  9. Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Hamilton Depression Rating Scale (HAM-D17) Score.

    The HAM-D17 is utilized as a secondary assessment of a participant's level of depression. The HAM-D (17-Item) consists of 17 items. Eight items are rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) are rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 is the "best" rating and the highest score (2 or 4) is the "worst" rating. The possible total scores are from 0 to 52.

    Time frame: Week 8 to Week 14

  10. Clinical Global Impression-Improvement Scale (CGI-I) Score at Each Study Week Visit in Phase B.

    CGI-I items are: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse. The score of 0 (= not assessed) will be set to missing. The CGI-I is therefore a 7-point scale from 1 through 7. CGI-I was assessed at each visit in Phase B, and improvement is judged with respect to the participant's condition at baseline. CGI-I was also assessed at each visit in Phase B, but in that phase improvement is judged with respect to the partcipant's condition at the end of Phase A.

    Time frame: Week 8 to each of Week 9, 10, 11, 12, 13 and 14.

  11. Percentage of Participants With MADRS Response From End of Phase A (Week 8 Visit).

    A MADRS response was defined as \>/= 50% reduction in MADRS Total Score from end of Phase A (Week 8 visit).

    Time frame: Week 8 to each of Week 9, 10, 11, 12, 13 and 14.

  12. Percentage of Participants With MADRS Remission From End of Phase A (Week 8 Visit).

    A MADRS remission was defined as MADRS Total Score \</= 10 and \>/= 50% reduction in MADRS Total Score from end of Phase A (Week 8 visit).

    Time frame: Week 8 to each of Week 9, 10, 11, 12, 13 and 14.

  13. Percentage of Participants With CGI-I Response From End of Phase A (Week 8 Visit).

    CGI-I response is defined as CGI-I of 1 \[very much improved\] or 2 \[much improved\].

    Time frame: Week 9, 10, 11, 12, 13 and 14.

07

Results

Posted Dec 3, 2015

Participant flow

This study was a Phase 2, multicenter, randomized, double-blind, placebo-controlled study of the safety and efficacy of OPC-34712 as adjunctive therapy in the treatment of participants with major depressive disorder. This study was conducted in the United States at 50 study centers.

Phase A
Participant flow — Phase A
MilestoneOPC-34712 0.15 mg Fixed DoseOPC-34712 0.5 ± 0.25 mg Low DoseOPC-34712 1.5 ± 0.5 mg High DosePlaceboParticipants in Phase AParticipants in Phase A+
Started00008490
Completed00006640
Not completed00001850
Withdrew: Lost to follow-up0000330
Withdrew: Adverse event0000460
Withdrew: Met withdrawal criteria000040
Withdrew: Physician decision0000130
Withdrew: Withdrawal by subject0000330
Withdrew: Protocol deviation0000560
Phase B
Participant flow — Phase B
MilestoneOPC-34712 0.15 mg Fixed DoseOPC-34712 0.5 ± 0.25 mg Low DoseOPC-34712 1.5 ± 0.5 mg High DosePlaceboParticipants in Phase AParticipants in Phase A+
Started6212012112600
Completed5110210011000
Not completed1118211600
Withdrew: Lost to follow-up013000
Withdrew: Adverse event213100
Withdrew: Met withdrawal criteria336100
Withdrew: Physician decision103100
Withdrew: Withdrawal by subject143300
Withdrew: Protocol deviation482600
Withdrew: Lack of efficacy011400
Phase A+
Participant flow — Phase A+
MilestoneOPC-34712 0.15 mg Fixed DoseOPC-34712 0.5 ± 0.25 mg Low DoseOPC-34712 1.5 ± 0.5 mg High DosePlaceboParticipants in Phase AParticipants in Phase A+
Started00000235
Completed00000207
Not completed0000028
Withdrew: Lost to follow-up000009
Withdrew: Met withdrawal criteria000005
Withdrew: Withdrawal by subject000006
Withdrew: Adverse event000004
Withdrew: Protocol deviation000004

Outcome measures

PrimaryChange From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score.

The MADRS is utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items. The possible Total scores are from 0 to 60. The MADRS Total Score was unevaluable if less than 8 of the 10 items are recorded. If 8 or 9 of the 10 items were recorded, the MADRS Total Score was the mean of the recorded items multiplied by 10 and then rounded to the first decimal place.

Time frame:
Week 8 to Week 14
Reported as:
Least squares mean · Units on a scale
Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score.
Units on a scaleOPC-34712 0.15 mg Fixed DoseOPC-34712 0.5 ± 0.25 mg Low DoseOPC-34712 1.5 ± 0.5 mg High DosePlacebo
Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score.-6.62 ± 0.99-6.46 ± 0.73-8.23 ± 0.74-6.09 ± 0.72
Statistical analysis
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · ANCOVA · p = 0.6551 · Mean difference (final values): -0.53 · 95% CI -2.87 to 1.81
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · ANCOVA · p = 0.7037 · Mean difference (final values): -0.37 · 95% CI -2.30 to 1.55
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · ANCOVA · p = 0.0303 · Mean difference (final values): -2.14 · 95% CI -4.08 to -0.21
SecondaryChange From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Clinical Global Impression - Severity of Illness Scale (CGI-S) Score.

CGI-S items are: 0 = not assessed, 1 = normal, not at all ill, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill patients. The score 0 (= not assessed) was set to missing. The CGI-S was therefore a 7-point scale from 1 through 7. CGI-S was assessed at screening, baseline and each subsequent visit from Week 1 through Week 14.

Time frame:
Week 8 to Week 14
Reported as:
Least squares mean · Units on a scale
Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Clinical Global Impression - Severity of Illness Scale (CGI-S) Score.
Units on a scaleOPC-34712 0.15 mg Fixed DoseOPC-34712 0.5 ± 0.25 mg Low DoseOPC-34712 1.5 ± 0.5 mg High DosePlacebo
Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Clinical Global Impression - Severity of Illness Scale (CGI-S) Score.-0.83 ± 0.13-0.81 ± 0.10-1.06 ± 0.10-0.71 ± 0.09
Statistical analysis
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · ANCOVA · p = 0.4166 · Mean difference (final values): -0.13 · 95% CI -0.43 to 0.18Treatment difference = difference in adjusted mean change: OPC-34712 - placebo
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · ANCOVA · p = 0.4193 · Mean difference (final values): -0.10 · 95% CI -0.35 to 0.15Treatment difference = difference in adjusted mean change: OPC-34712 - placebo.
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · ANCOVA · p = 0.0064 · Mean difference (final values): -0.35 · 95% CI -0.60 to -0.10Treatment difference = difference in adjusted mean change: OPC-34712 - placebo.
SecondaryChange From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Quality of Life, Enjoyment, and Satisfaction Questionnaire - Short Form (QLES-Q-SF) Subscale Score - the Overall General Subscore (Sum of First 14 Items).

The Q-LES-Q is a self-report measure to enable physicians to obtain sensitive measures of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning. Each item is scored on a five-point scale, with 1= Very Poor; 2=Poor; 3=Fair; 4=Good; 5=Very Good. Lower scores indicating less enjoyment or satisfaction with the activity. The Overall-General Subscore will be defined by summing the scores on all 14 items and expressing it as the percent of the maximum possible score. When expressing the total score as a percentage, if items are left blank the range will be modified to reflect the number of items scored. Raw score is sum of non-missing ratings from items 1 to 14. Minimum score is number of non-missing items. Maximum score is 5\*(minimum score). Range is maximum score minus minimum score. Total score is 100\*(Raw score minus minimum score)/ Range, rounded to nearest integer.

Time frame:
Week 8 to Week 14
Reported as:
Least squares mean · Percentage of maximum possible score
Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Quality of Life, Enjoyment, and Satisfaction Questionnaire - Short Form (QLES-Q-SF) Subscale Score - the Overall General Subscore (Sum of First 14 Items).
Percentage of maximum possible scoreOPC-34712 0.15 mg Fixed DoseOPC-34712 0.5 ± 0.25 mg Low DoseOPC-34712 1.5 ± 0.5 mg High DosePlacebo
Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Quality of Life, Enjoyment, and Satisfaction Questionnaire - Short Form (QLES-Q-SF) Subscale Score - the Overall General Subscore (Sum of First 14 Items).7.60 ± 1.826.53 ± 1.387.46 ± 1.385.92 ± 1.34
Statistical analysis
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · ANCOVA · p = 0.4490 · Mean difference (final values): 1.68 · 95% CI -2.67 to 6.02Treatment difference = difference in adjusted mean change: OPC-34712 - placebo.
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · ANCOVA · p = 0.7412 · Mean difference (final values): 0.61 · 95% CI -3.02 to 4.24Treatment difference = difference in adjusted mean change: OPC-34712 - placebo.
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · ANCOVA · p = 0.4070 · Mean difference (final values): 1.54 · 95% CI -2.10 to 5.17Treatment difference = difference in adjusted mean change: OPC-34712 - placebo.
SecondaryChange From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Sheehan Disability Scale (SDS) Mean Score (the Mean of 3 Individual Item Scores).

The Sheehan Disability Scale (SDS) is a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS Score will be calculated over the three item scores. All three item scores need to be available with the exception of the work/school item score when this item is not applicable.

Time frame:
Week 8 to Week 14
Reported as:
Least squares mean · Units on a scale
Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Sheehan Disability Scale (SDS) Mean Score (the Mean of 3 Individual Item Scores).
Units on a scaleOPC-34712 0.15 mg Fixed DoseOPC-34712 0.5 ± 0.25 mg Low DoseOPC-34712 1.5 ± 0.5 mg High DosePlacebo
Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Sheehan Disability Scale (SDS) Mean Score (the Mean of 3 Individual Item Scores).-0.84 ± 0.27-0.80 ± 0.21-1.27 ± 0.20-0.61 ± 0.20
Statistical analysis
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · ANCOVA · p = 0.4954 · Mean difference (final values): -0.22 · 95% CI -0.86 to 0.42Treatment difference = difference in adjusted mean change: OPC-34712 - placebo.
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · ANCOVA · p = 0.4902 · Mean difference (final values): -0.19 · 95% CI -0.73 to 0.35Treatment difference = difference in adjusted mean change: OPC-34712 - placebo.
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · ANCOVA · p = 0.0161 · Mean difference (final values): -0.66 · 95% CI -1.20 to -0.12Treatment difference = difference in adjusted mean change: OPC-34712 - placebo.
SecondaryChange From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Study Week Visit in Phase B Other Than the Week 14 Visit.

The MADRS is utilized as the primary efficacy assessment of a patient's level of depression. The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items. The possible Total scores are from 0 to 60. The MADRS Total Score was unevaluable if less than 8 of the 10 items are recorded. If 8 or 9 of the 10 items were recorded, the MADRS Total Score was the mean of the recorded items multiplied by 10 and then rounded to the first decimal place.

Time frame:
Week 8 to each of Week 9, 10, 11, 12 and 13.
Reported as:
Mean · Units on a scale
Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Study Week Visit in Phase B Other Than the Week 14 Visit.
Units on a scaleOPC-34712 0.15 mg Fixed DoseOPC-34712 0.5 ± 0.25 mg Low DoseOPC-34712 1.5 ± 0.5 mg High DosePlacebo
Week 9 (N=61,117,116,121)-2.13 ± 5.22-3.00 ± 5.13-2.75 ± 5.32-2.48 ± 5.43
Week 10 (N=62,119,118,126)-3.69 ± 5.34-3.78 ± 6.27-4.97 ± 6.48-3.64 ± 6.65
Week 11 (N=62,119,118,126)-5.53 ± 7.24-5.71 ± 7.15-5.88 ± 7.09-4.40 ± 7.05
Week 12 (N=62,119,118,126)-6.97 ± 7.65-6.31 ± 6.72-7.01 ± 7.58-4.41 ± 6.74
Week 13 (N=62,119,118,126)-6.90 ± 7.71-6.76 ± 7.20-7.18 ± 7.64-5.47 ± 7.47
SecondaryChange From End of Phase A (Week 8 Visit) in Mean CGI-S Score for Every Study Week Visit in Phase B Other Than the Week 14 Visit.

CGI-S items are: 0 = not assessed, 1 = normal, not at all ill, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill patients. The score 0 (= not assessed) was set to missing. The CGI-S was therefore a 7-point scale from 1 through 7. CGI-S was assessed at screening, baseline and each subsequent visit from Week 1 through Week 14.

Time frame:
Week 8 to each of Week 9, 10, 11, 12 and 13.
Reported as:
Mean · Units on a scale
Change From End of Phase A (Week 8 Visit) in Mean CGI-S Score for Every Study Week Visit in Phase B Other Than the Week 14 Visit.
Units on a scaleOPC-34712 0.15 mg Fixed DoseOPC-34712 0.5 ± 0.25 mg Low DoseOPC-34712 1.5 ± 0.5 mg High DosePlacebo
Week 9 (N=62,117,116,121)-0.21 ± 0.60-0.26 ± 0.57-0.33 ± 0.64-0.21 ± 0.58
Week 10 (N=62,119,118,126)-0.42 ± 0.74-0.39 ± 0.77-0.61 ± 0.91-0.40 ± 0.87
Week 11 (N=62,119,118,126)-0.53 ± 0.95-0.53 ± 0.84-0.69 ± 0.92-0.47 ± 0.89
Week 12 (N=62,119,118,126)-0.76 ± 1.02-0.66 ± 0.87-0.86 ± 1.00-0.52 ± 0.98
Week 13 (N=62,119,118,126)-0.74 ± 1.09-0.78 ± 0.95-0.88 ± 1.01-0.59 ± 1.04
SecondaryChange From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 15 Score (Satisfaction With Medication).

The Q-LES-Q (Short Form) is a self-report measure designed to enable physicians to easily obtain sensitive measures of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning. Each item is scored on a five-point scale, with 1= Very Poor; 2=Poor; 3=Fair; 4=Good; 5=Very Good. Lower scores indicating less enjoyment or satisfaction with the activity. According to the scoring system suggested for this questionnaire, item 15 (Satisfaction with Medication) will yield a separate subscore.

Time frame:
Week 8 to Week 14
Reported as:
Mean · Units on a scale
Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 15 Score (Satisfaction With Medication).
Units on a scaleOPC-34712 0.15 mg Fixed DoseOPC-34712 0.5 ± 0.25 mg Low DoseOPC-34712 1.5 ± 0.5 mg High DosePlacebo
Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 15 Score (Satisfaction With Medication).0.02 ± 0.220.01 ± 0.250.02 ± 0.330.00 ± 0.22
SecondaryChange From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 16 Score (Overall Life Satisfaction).

The Q-LES-Q (Short Form) is a self-report measure designed to enable physicians to easily obtain sensitive measures of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning. Each item is scored on a five-point scale, with 1= Very Poor; 2=Poor; 3=Fair; 4=Good; 5=Very Good. Lower scores indicating less enjoyment or satisfaction with the activity. According to the scoring system suggested for this questionnaire, item 16 (Overall Life Satisfaction) will yield a separate subscore.

Time frame:
Week 8 to Week 14
Reported as:
Mean · Units on a scale
Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 16 Score (Overall Life Satisfaction).
Units on a scaleOPC-34712 0.15 mg Fixed DoseOPC-34712 0.5 ± 0.25 mg Low DoseOPC-34712 1.5 ± 0.5 mg High DosePlacebo
Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 16 Score (Overall Life Satisfaction).0.30 ± 0.840.30 ± 0.790.35 ± 0.930.28 ± 1.00
SecondaryChange From End of Phase A (Week 8 Visit) for Every Study Week Visit in Phase B in Inventory of Depressive Symptomatology (Self-Report) (IDS-SR) Total Score.

The IDS-SR is a 30-item self-report measure used to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of major depressive disorders. The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. The IDS-SR Total Score is the sum of ratings of 28 item scores. The possible IDS-SR Total Score ranges from 0 to 84. The IDS-SR Total Score was un-evaluable if less than 23 of the 28 items are recorded. If the number of items was at least 23 and at most 27, the IDS-SR Total Score will be the mean of the recorded items multiplied by 28 and then rounded to the first decimal place.

Time frame:
Week 8 to each of Week 9, 10, 11, 12, 13 and 14
Reported as:
Mean · Units on a scale
Change From End of Phase A (Week 8 Visit) for Every Study Week Visit in Phase B in Inventory of Depressive Symptomatology (Self-Report) (IDS-SR) Total Score.
Units on a scaleOPC-34712 0.15 mg Fixed DoseOPC-34712 0.5 ± 0.25 mg Low DoseOPC-34712 1.5 ± 0.5 mg High DosePlacebo
Week 9 (N=61, 117,116,121)-0.98 ± 7.28-1.88 ± 6.60-2.04 ± 5.93-0.98 ± 7.58
Week 10 (N=62, 119, 118, 126)-2.13 ± 8.02-2.58 ± 7.37-4.08 ± 7.25-1.62 ± 7.76
Week 11 (N=62, 119, 118, 126)-3.58 ± 7.81-3.41 ± 7.88-4.82 ± 7.96-2.09 ± 8.42
Week 12 (N=62, 119, 118, 126)-5.11 ± 9.42-3.77 ± 8.45-5.77 ± 9.26-2.07 ± 8.42
Week 13 (N=62, 119, 118, 126)-5.34 ± 9.15-5.22 ± 8.72-5.65 ± 8.84-2.37 ± 8.45
Week 14 (N=62, 119, 118, 126)-5.55 ± 9.65-4.96 ± 9.37-6.74 ± 9.76-3.08 ± 9.32
SecondaryChange From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Hamilton Depression Rating Scale (HAM-D17) Score.

The HAM-D17 is utilized as a secondary assessment of a participant's level of depression. The HAM-D (17-Item) consists of 17 items. Eight items are rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) are rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 is the "best" rating and the highest score (2 or 4) is the "worst" rating. The possible total scores are from 0 to 52.

Time frame:
Week 8 to Week 14
Reported as:
Least squares mean · Units on a scale
Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Hamilton Depression Rating Scale (HAM-D17) Score.
Units on a scaleOPC-34712 0.15 mg Fixed DoseOPC-34712 0.5 ± 0.25 mg Low DoseOPC-34712 1.5 ± 0.5 mg High DosePlacebo
Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Hamilton Depression Rating Scale (HAM-D17) Score.-5.77 ± 0.86-5.28 ± 0.63-6.59 ± 0.62-5.23 ± 0.59
Statistical analysis
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · ANCOVA · p = 0.5953 · Mean difference (final values): -0.54 · 95% CI -2.54 to 1.46Treatment difference = difference in adjusted mean change: OPC-34712 - placebo.
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · ANCOVA · p = 0.9479 · Mean difference (final values): -0.05 · 95% CI -1.66 to 1.55Treatment difference = difference in adjusted mean change: OPC-34712 - placebo.
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · ANCOVA · p = 0.0919 · Mean difference (final values): -1.36 · 95% CI -2.95 to 0.22Treatment difference = difference in adjusted mean change: OPC-34712 - placebo.
SecondaryClinical Global Impression-Improvement Scale (CGI-I) Score at Each Study Week Visit in Phase B.

CGI-I items are: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse. The score of 0 (= not assessed) will be set to missing. The CGI-I is therefore a 7-point scale from 1 through 7. CGI-I was assessed at each visit in Phase B, and improvement is judged with respect to the participant's condition at baseline. CGI-I was also assessed at each visit in Phase B, but in that phase improvement is judged with respect to the partcipant's condition at the end of Phase A.

Time frame:
Week 8 to each of Week 9, 10, 11, 12, 13 and 14.
Reported as:
Mean · Units on a scale
Clinical Global Impression-Improvement Scale (CGI-I) Score at Each Study Week Visit in Phase B.
Units on a scaleOPC-34712 0.15 mg Fixed DoseOPC-34712 0.5 ± 0.25 mg Low DoseOPC-34712 1.5 ± 0.5 mg High DosePlacebo
Week 9 (N=62, 117, 116, 121)3.39 ± 0.863.30 ± 0.793.20 ± 0.803.31 ± 0.79
Week 10 (N=62, 119, 118, 126)3.16 ± 0.943.19 ± 0.902.95 ± 0.933.11 ± 1.04
Week 11 (N=62, 119, 118, 126)2.94 ± 0.943.02 ± 0.982.80 ± 0.922.94 ± 1.01
Week 12 (N=62, 119, 118, 126)2.87 ± 1.062.90 ± 0.992.70 ± 1.032.95 ± 1.06
Week 13 (N=62, 119, 118, 126)2.85 ± 1.132.76 ± 1.022.64 ± 1.062.90 ± 1.14
Week 14 (N=62, 119, 118, 126)2.74 ± 1.162.78 ± 1.022.52 ± 1.082.83 ± 1.12
Statistical analysis
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.3998 (Cochran-Mantel-Haenszel row mean scores differ test controlling for study center.)
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.8838 (Cochran-Mantel-Haenszel row mean scores differ test controlling for study center.)
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.4012 (Cochran-Mantel-Haenszel row mean scores differ test controlling for study center.)
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.6131 (Cochran-Mantel-Haenszel row mean scores differ test controlling for study center.)
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.5964 (Cochran-Mantel-Haenszel row mean scores differ test controlling for study center.)
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.2540 (Cochran-Mantel-Haenszel row mean scores differ test controlling for study center.)
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.8524 (Cochran-Mantel-Haenszel row mean scores differ test controlling for study center.)
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.6969 (Cochran-Mantel-Haenszel row mean scores differ test controlling for study center.)
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.3108 (Cochran-Mantel-Haenszel row mean scores differ test controlling for study center.)
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.8719 (Cochran-Mantel-Haenszel row mean scores differ test controlling for study center.)
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.6105 (Cochran-Mantel-Haenszel row mean scores differ test controlling for study center.)
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.0709 (Cochran-Mantel-Haenszel row mean scores differ test controlling for study center.)
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.9574 (Cochran-Mantel-Haenszel row mean scores differ test controlling for study center.)
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.2310 (Cochran-Mantel-Haenszel row mean scores differ test controlling for study center.)
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.0672 (Cochran-Mantel-Haenszel row mean scores differ test controlling for study center.)
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.8441 (Cochran-Mantel-Haenszel row mean scores differ test controlling for study center.)
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.6741 (Cochran-Mantel-Haenszel row mean scores differ test controlling for study center.)
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.0183 (Cochran-Mantel-Haenszel row mean scores differ test controlling for study center.)
SecondaryPercentage of Participants With MADRS Response From End of Phase A (Week 8 Visit).

A MADRS response was defined as \>/= 50% reduction in MADRS Total Score from end of Phase A (Week 8 visit).

Time frame:
Week 8 to each of Week 9, 10, 11, 12, 13 and 14.
Reported as:
Number · Percentage of participants
Percentage of Participants With MADRS Response From End of Phase A (Week 8 Visit).
Percentage of participantsOPC-34712 0.15 mg Fixed DoseOPC-34712 0.5 ± 0.25 mg Low DoseOPC-34712 1.5 ± 0.5 mg High DosePlacebo
Week 9 (N=61, 117, 116, 121)4.926.842.598.26
Week 10 (N=62, 119, 118, 126)8.068.4011.09.52
Week 11 (N=62, 119, 118, 126)19.415.118.613.5
Week 12 (N=62, 119, 118, 126)30.615.125.411.9
Week 13 (N=62, 119, 118, 126)24.222.725.418.3
Week 14 (N=62, 119, 118, 126)27.420.234.719.8
Statistical analysis
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.3007 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 0.49 · 95% CI 0.12 to 1.93
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.8812 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 0.94 · 95% CI 0.42 to 2.10
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.0553 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 0.32 · 95% CI 0.10 to 1.07
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.6051 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 0.78 · 95% CI 0.30 to 2.05
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.8264 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 0.92 · 95% CI 0.46 to 1.85
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.8690 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 1.06 · 95% CI 0.54 to 2.10
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.3441 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 1.35 · 95% CI 0.74 to 2.44
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.6375 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 1.14 · 95% CI 0.67 to 1.94
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.3135 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 1.31 · 95% CI 0.78 to 2.21
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.0035 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 2.35 · 95% CI 1.32 to 4.18
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.4358 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 1.27 · 95% CI 0.70 to 2.31
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.0063 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 2.02 · 95% CI 1.20 to 3.41
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.3968 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 1.27 · 95% CI 0.72 to 2.23
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.2990 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 1.27 · 95% CI 0.81 to 2.00
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.1614 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 1.39 · 95% CI 0.86 to 2.25
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.3254 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 1.29 · 95% CI 0.79 to 2.12
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.9463 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 1.02 · 95% CI 0.64 to 1.62
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.0080 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 1.74 · 95% CI 1.14 to 2.65
SecondaryPercentage of Participants With MADRS Remission From End of Phase A (Week 8 Visit).

A MADRS remission was defined as MADRS Total Score \</= 10 and \>/= 50% reduction in MADRS Total Score from end of Phase A (Week 8 visit).

Time frame:
Week 8 to each of Week 9, 10, 11, 12, 13 and 14.
Reported as:
Number · Percentage of participants
Percentage of Participants With MADRS Remission From End of Phase A (Week 8 Visit).
Percentage of participantsOPC-34712 0.15 mg Fixed DoseOPC-34712 0.5 ± 0.25 mg Low DoseOPC-34712 1.5 ± 0.5 mg High DosePlacebo
Week 9 (N=61, 117, 116, 121)3.281.711.724.13
Week 10 (N=62, 119, 118, 126)8.065.0410.28.73
Week 11 (N=62, 119, 118, 126)12.910.114.411.1
Week 12 (N=62, 119, 118, 126)21.010.119.510.3
Week 13 (N=62, 119, 118, 126)19.416.815.315.1
Week 14 (N=62, 119, 118, 126)22.615.123.713.5
Statistical analysis
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.5791 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of remission rate: 0.59 · 95% CI 0.09 to 3.90
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.2653 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of remission rate: 0.43 · 95% CI 0.10 to 1.93
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.2259 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of remission rate: 0.39 · 95% CI 0.08 to 1.87
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.6986 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of remission rate: 0.83 · 95% CI 0.32 to 2.18
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.2339 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of remission rate: 0.61 · 95% CI 0.28 to 1.35
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.8615 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of remission rate: 1.07 · 95% CI 0.53 to 2.15
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.8807 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of remission rate: 1.06 · 95% CI 0.51 to 2.20
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.9035 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of remission rate: 0.96 · 95% CI 0.52 to 1.77
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.5898 · Ratio of remission rate: 1.19 · 95% CI 0.64 to 2.24
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.0840 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of remission rate: 1.82 · 95% CI 0.93 to 3.58
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.9115 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of remission rate: 0.96 · 95% CI 0.49 to 1.88
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.0522 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of remission rate: 1.77 · 95% CI 0.98 to 3.17
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.4997 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of remission rate: 1.24 · 95% CI 0.65 to 2.34
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.5846 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of remission rate: 1.16 · 95% CI 0.69 to 1.93
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.9602 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of remission rate: 0.99 · 95% CI 0.55 to 1.76
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.1254 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of remission rate: 1.62 · 95% CI 0.87 to 3.02
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.6670 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of remission rate: 1.13 · 95% CI 0.65 to 1.99
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.0525 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of remission rate: 1.70 · 95% CI 0.98 to 2.93
SecondaryPercentage of Participants With CGI-I Response From End of Phase A (Week 8 Visit).

CGI-I response is defined as CGI-I of 1 \[very much improved\] or 2 \[much improved\].

Time frame:
Week 9, 10, 11, 12, 13 and 14.
Reported as:
Number · percentage of participants
Percentage of Participants With CGI-I Response From End of Phase A (Week 8 Visit).
percentage of participantsOPC-34712 0.15 mg Fixed DoseOPC-34712 0.5 ± 0.25 mg Low DoseOPC-34712 1.5 ± 0.5 mg High DosePlacebo
Week 9 (N=62, 117, 116, 121)16.111.114.714.9
Week 10 (N=62, 119, 118, 126)25.817.624.627.0
Week 11 (N=62, 119, 118, 126)32.329.435.629.4
Week 12 (N=62, 119, 118, 126)35.533.642.431.7
Week 13 (N=62, 119, 118, 126)37.137.049.233.3
Week 14 (N=62, 119, 118, 126)38.737.052.541.3
Statistical analysis
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.9462 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 0.98 · 95% CI 0.52 to 1.84
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.4971 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 0.80 · 95% CI 0.43 to 1.49
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.8118 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 0.93 · 95% CI 0.53 to 1.63
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.8323 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 0.95 · 95% CI 0.59 to 1.53
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.0930 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 0.68 · 95% CI 0.43 to 1.08
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.5530 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 0.88 · 95% CI 0.59 to 1.32
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.8007 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 1.06 · 95% CI 0.69 to 1.61
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.8945 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 1.03 · 95% CI 0.71 to 1.49
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.3837 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 1.17 · 95% CI 0.83 to 1.64
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.7064 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 1.09 · 95% CI 0.72 to 1.63
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.7469 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 1.06 · 95% CI 0.74 to 1.52
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.0832 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 1.34 · 95% CI 0.97 to 1.86
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.6611 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 1.09 · 95% CI 0.74 to 1.61
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.4435 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 1.13 · 95% CI 0.83 to 1.56
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.0118 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 1.47 · 95% CI 1.09 to 1.98
  • OPC-34712 0.15 mg Fixed Dose vs Placebo · Chi-squared, Corrected · p = 0.5111 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 0.89 · 95% CI 0.63 to 1.26
  • OPC-34712 0.5 ± 0.25 mg Low Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.4903 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 0.90 · 95% CI 0.66 to 1.22
  • OPC-34712 1.5 ± 0.5 mg High Dose vs Placebo · Cochran-Mantel-Haenszel · p = 0.0662 (Cochran-Mantel-Haenszel general association test controlling for study center.) · Ratio of response rate: 1.28 · 95% CI 0.98 to 1.67

Adverse events

Collected over From Randomization to 30 (+2) days after the end of Phase B (Week 14/End of treatment).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OPC-34712 0.15 mg Fixed Dose—0/62 (0%)21/62 (33.9%)
OPC-34712 0.5 ± 0.25 mg Low Dose—0/120 (0%)37/120 (30.8%)
OPC-34712 1.5 ± 0.5 mg High Dose—2/121 (1.7%)47/121 (38.8%)
Placebo—1/126 (0.8%)37/126 (29.4%)
Most frequent serious events
Most frequent serious events
EventOPC-34712 0.15 mg Fixed DoseOPC-34712 0.5 ± 0.25 mg Low DoseOPC-34712 1.5 ± 0.5 mg High DosePlacebo
Radius fractureInjury, poisoning and procedural complications0/620/1201/1210/126
Ulna fractureInjury, poisoning and procedural complications0/620/1201/1210/126
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/620/1201/1210/126
Renal massRenal and urinary disorders0/620/1200/1211/126
Most frequent other events
Most frequent other events
EventOPC-34712 0.15 mg Fixed DoseOPC-34712 0.5 ± 0.25 mg Low DoseOPC-34712 1.5 ± 0.5 mg High DosePlacebo
HeadacheNervous system disorders5/629/1206/12112/126
Upper respiratory tract infectionInfections and infestations4/6210/1207/1216/126
DiarrhoeaGastrointestinal disorders1/620/12010/1215/126
AkathisiaNervous system disorders4/626/12010/1214/126
InsomniaPsychiatric disorders5/623/1204/1214/126
Weight increasedInvestigations3/627/1209/1211/126
RestlessnessPsychiatric disorders4/621/1205/1216/126
NauseaGastrointestinal disorders0/627/1202/1213/126
NasopharyngitisInfections and infestations3/627/1205/1212/126

Baseline characteristics

Age, Continuous
Age, Continuous(Years)OPC-34712 0.15 mg Fixed DoseOPC-34712 0.5 ± 0.25 mg Low DoseOPC-34712 1.5 ± 0.5 mg High DosePlaceboTotal
Mean43.9 ± 10.844.0 ± 11.843.7 ± 11.643.3 ± 11.543.7 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)OPC-34712 0.15 mg Fixed DoseOPC-34712 0.5 ± 0.25 mg Low DoseOPC-34712 1.5 ± 0.5 mg High DosePlaceboTotal
Female41868082289
Male21344144140
08

Study locations

50 sites
  • Pacific Clinical Research Medical Group
    Arcadia, California 91007, United States
  • Southwestern Research
    Beverly Hills, California 90210, United States
  • Synergy Escondido
    Escondido, California 92025, United States
  • Collaborative Neuroscience Network Inc.
    Garden Grove, California 92845, United States
  • Synergy Clinical Research Center
    National City, California 91950, United States
  • Excell Research
    Oceanside, California 92056, United States
  • Affiliated Research Institute
    San Diego, California 92108, United States
  • California Neuroscience Research Medical Group, Inc.
    Sherman Oaks, California 91403, United States
  • Radiant Research Center
    Denver, Colorado 80239, United States
  • Florida Clinical Research Center, LLC
    Bradenton, Florida 34208, United States
  • CNS Clinical Research Group
    Coral Springs, Florida 33065, United States
  • Gulfcoast Clinical Research Center
    Fort Myers, Florida 33912, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32216, United States
  • Accurate Clinical Trials
    Kissimee, Florida 34741, United States
  • Clinical Neurosciences Solutions
    Orlando, Florida 32806, United States
  • Stedman Clinical Trials
    Tampa, Florida 33613, United States
  • University of South Florida College of Medicine Psychiatry Center
    Tampa, Florida 33613, United States
  • Janus Center
    West Palm Beach, Florida 33407, United States
  • Carman Research
    Smyrna, Georgia 30080, United States
  • Uptown Research Institute
    Chicago, Illinois 60640, United States
  • Midwest Center for Neurobehavioral Medicine
    Oakbrook Terrace, Illinois 60181, United States
  • The Davis Clinic, PC
    Indianapolis, Indiana 46260, United States
  • Vince & Associates Clinical Research
    Overland Park, Kansas 66212, United States
  • Pharmasite Research, Inc.
    Baltimore, Maryland 21208, United States
  • Bioscience Research
    Mount Kisco, New York 10549, United States
  • Eastside Comprehensive Medical Center
    New York City, New York 10021, United States
  • Medical & Behavioral Health Research, PC
    New York, New York 10023, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618, United States
  • Carolinas HealthCare - Behavioral Heath Center
    Charlotte, North Carolina 28211, United States
  • NorthCoast Clinical Trials, Inc
    Beachwood, Ohio 44122, United States
  • Neuro-Behavioral Clinical Research, Inc
    Canton, Ohio 44718, United States
  • Patient Priority Clinical Sites, LLC
    Cinncinnati, Ohio 45242, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45408, United States
  • NorthStar Medical Research, LLC
    Middleburg Heights, Ohio 44130, United States
  • Summitt Research Network (Oregon)
    Portland, Oregon 97210, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • USC School of Medicine- Department of Neuropsychiatry and Behavioral Science
    Columbia, South Carolina 29203, United States
  • Clinical Neurosciences Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • Community Clinical Research, Inc.
    Austin, Texas 78754, United States
  • FutureSearch Clinical Trials
    Austin, Texas 78756, United States
  • Radiant Research
    Salt Lake City, Utah 84107, United States
  • Mood Disorders Clinic
    Salt Lake City, Utah 84132, United States
  • Psychiatric Alliance of the Blue Ridge
    Charlottesville, Virginia 22903, United States
  • NeuroScience, Inc.
    Herndon, Virginia 20170, United States
  • Dominion Clinical Research
    Midlothian, Virginia 23112, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Summit Research Network (Seattle) LLC
    Seattle, Washington, United States
  • Northbrooke Research Center
    Brown Deer, Wisconsin 53223, United States
  • Dean Foundation
    Middleton, Wisconsin 53562, United States
09

References and documents

Publications

  • Hobart M, Zhang P, Weiss C, Meehan SR, Eriksson H. Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale. Int J Neuropsychopharmacol. 2019 Mar 1;22(3):173-179. doi: 10.1093/ijnp/pyy095. PubMed 30508090 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Jun 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 5 years 6 months after primary completion. A results delay was requested in May 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2008
First posted
Nov 25, 2008
Start
May 2009
Primary completionActual
Jun 2010
CompletionActual
Jul 2010
Results delay requested
May 10, 2012
Results first posted
Dec 3, 2015
Last update
Feb 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00797966
Responsible party
Sponsor
First posted
Nov 25, 2008
Start date
May 2009
Primary completion
Jun 2010
Completion
Jul 2010
Results posted
Dec 3, 2015
Last update
Feb 29, 2016

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion